Galloway Capital Partners Discloses 8.42% Stake in WW International and Issues Letter to Management

On May 13, 2026, Galloway Capital Partners, LLC, along with its affiliates and Bruce Galloway, filed a Schedule 13D disclosing an 8.42% beneficial ownership stake in WW International, Inc. (WW). The reporting persons hold 378,700 shares of common stock and 463,000 shares underlying call options exercisable within 60 days. Galloway acquired these securities for investment purposes, citing that the company is materially undervalued relative to its intrinsic value and strategic positioning in the GLP-1 and clinical weight management sectors. In an attached letter to WW's Chairman, Galloway highlighted the company's improved capital structure following a debt reduction from $1.4 billion to $460 million. Despite this, the market capitalization has fallen significantly, with the stock trading at approximately 3.7x EBITDA. Galloway intends to engage constructively with the Board and management regarding performance, governance, and potential strategic alternatives. They specifically emphasized the value of WW's 2.7 million-member ecosystem and the need for a world-class CEO to lead the digital health transformation.